In this category the supply chain matters more than the molecule, because the molecules have so little human evidence behind them that the main variable left is whether what arrives is sterile, correctly identified, and legally dispensed. Three things decide that: which pharmacy prepared it, which clinician authorized it, and how it traveled.
Two kinds of compounding pharmacy, two sets of rules
Compounding in the United States runs through two sections of federal law. A traditional pharmacy operating under section 503A prepares a preparation for an identified patient against a prescription and is regulated mainly by its state board. An outsourcing facility operating under section 503B registers with FDA, produces in batches, and is subject to current good manufacturing practice requirements and FDA inspection.
Neither route produces an FDA-approved drug. Compounded preparations are not reviewed by FDA for safety, effectiveness, or quality before they reach a patient, which is why the identity and record of the preparing facility carries so much weight. FDA maintains published lists of bulk drug substances nominated for compounding use, sorted into categories, and a separate list of substances that may present significant safety risks.
Several peptides sold for energy and recovery sit on that risk list, among them MOTS-c, BPC-157, CJC-1295, ipamorelin acetate, AOD-9604, and thymosin beta-4 fragment. The stated concerns are immunogenicity by certain routes, peptide-related impurities, and difficulty characterizing the active ingredient. For MOTS-c the agency also records that it identified no human exposure data for any route of administration.
See also: Colocation Space: A Complete Guide for Modern Businesses
What the evidence gap means for sourcing
| Compound | How it usually reaches a buyer | Human data available |
|---|---|---|
| MOTS-c | Compounding pharmacy by prescription, or a research-chemical vendor with no prescription | None from administration studies; FDA records no human exposure data by any route |
| SS-31 (elamipretide) | Now an approved product for one rare inherited disorder, otherwise gray market | Substantial. Its phase 3 trial in primary mitochondrial myopathy did not beat placebo on walking distance or fatigue |
| NAD+ for infusion | Wellness clinic or mobile infusion service | A systematic review found no eligible outcomes trials of injected NAD+ for wellness indications |
| NAD+ precursors | Retail dietary supplement | Blood NAD+ rises consistently; functional benefit remains unsettled |
| 5-Amino-1MQ | Capsules sold as a supplement or a research chemical | None. Published work is limited to cells and rodents |
| CJC-1295 and ipamorelin | Compounding pharmacy or research-chemical vendor | No published outcome data for energy in adults with normal pituitary function |
Verifying the pharmacy is a short task
Every state board of pharmacy publishes a license lookup. A legitimate service can name the pharmacy that fills its orders, and that name can be checked against the board register in the state where the pharmacy sits and, usually, in the patient’s own state as a nonresident license. Large compounding operations that come up in this market include Empower Pharmacy, Hallandale Pharmacy, and Tailor Made Compounding, and their status can be looked up the same way.
Refusal to name the pharmacy is the signal. Nobody can check inspection history, disciplinary actions, or outsourcing facility registration for a facility that stays anonymous. The question worth putting directly to the provider behind it is which pharmacy prepares the order and under which section of the compounding law it operates, since the answer determines what oversight applies.
Prescriber standards, and why the intake format matters
A prescription requires a clinician licensed in the patient’s state and a legitimate patient relationship. In practice the models vary widely, from a synchronous video consultation with chart review to a questionnaire that no human reads closely. Clinicians writing about direct-to-consumer telehealth have argued that convenience models need explicit guardrails around evidence-based prescribing, and the concern is sharpest where the requested product has no evidence base to prescribe against.
For fatigue specifically, a prescriber who does not ask about sleep, screen for sleep apnea, review current medications, or order basic labs is not evaluating the complaint. Anemia, thyroid disease, depression, and untreated sleep disorders are common and treatable, and none of them is found by an intake form that only asks which peptide the customer wants.
Fulfillment details that reveal the operation
A compounded sterile preparation should arrive with a patient-specific label carrying the patient name, the preparing pharmacy’s name and contact details, the contents, a lot or reference number, and a beyond-use date. Sterile preparations have shorter beyond-use dates than manufactured drugs, which is one reason shipping speed and cold packs matter.
Vials that arrive with no pharmacy label, a generic printed sticker, or wording such as for research use only did not come through a prescription pathway. Analytical work on this gray market is not reassuring: a systematic screening of falsified polypeptide products bought from illegal internet pharmacies found large variation in active ingredient content plus small molecule contaminants and residual solvents, and a separate study found undeclared mannitol at high percentages in custom synthetic peptides ordered from commercial suppliers.
Preparation errors are not hypothetical either. A pharmacovigilance analysis of adverse event reports for compounded versus manufactured GLP-1 products found markedly higher reporting odds for preparation errors, contamination, and compounding or manufacturing issues in the compounded group. A poison control case series documented dosing errors with compounded semaglutide arising from unclear labeling and unit confusion.
A workable sequence before ordering anything
Get the fatigue evaluated first, with labs and a sleep history. Establish what the compound in question has actually been tested for in humans. Confirm the prescriber is licensed where the patient lives and has reviewed a chart rather than a checkout form. Confirm the pharmacy by name and license. Confirm that the shipment arrives labeled, sealed, temperature-controlled, and traceable to a lot. Confirm there is a named clinician to contact if something goes wrong, and a route for reporting an adverse event to FDA.
Services that answer all six comfortably are not necessarily selling something that works. They are selling something that is at least accountable, which in a field this thin on evidence is the only quality that can be verified at all.
Accountability is also what separates the named services a buyer will compare. Direct-to-consumer prescribers such as Ro and Hims and Hers, longevity clinics such as Marek Health, and providers such as HealthRX, whose peptide therapy pages name the pharmacy model and the evidence behind each compound, can each be held to exactly the six questions above. A service that will not answer them in writing has told you how much oversight to expect.
Frequently asked questions
Is a 503B outsourcing facility better than a 503A pharmacy?
Different, not automatically better. Outsourcing facilities register with FDA, follow good manufacturing practice, and are inspected, which suits batch production. A 503A pharmacy prepares against an individual prescription under state board oversight. Neither produces an FDA-approved product, and both can be verified through public registers.
Does a certificate of analysis prove a vial is clean?
It proves something about the batch the supplier chose to test, using methods the supplier chose. Independent testing of a specific lot is stronger. Neither replaces a licensed pharmacy in the chain, since sterility depends on preparation conditions that no paper certificate captures.
What if the peptide is sold as a research chemical?
Then it was not dispensed as a medicine and carries no pharmacy accountability. Published analyses of internet-sourced peptides and growth hormone products have repeatedly found unlabeled contents, absent prescriptions, and poor storage. There is no recall pathway and no clinician attached to the transaction.
Should labs be required before a prescription for fatigue?
A prescriber treating fatigue without any laboratory workup is skipping the step most likely to help. Basic testing can surface anemia, thyroid dysfunction, and metabolic causes. Where a service refuses to order labs and prescribes anyway, that reveals the clinical model being run.
